Alnylam Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Unlock the Full Balanced Scorecard for Deeper Strategic Insight
This Alnylam Balanced Scorecard Analysis gives you a structured view of the company's financial, customer, internal process, and learning and growth priorities. The page already shows a real preview of the actual analysis, so you can review the content and format before buying. Purchase the full version to get the complete ready-to-use report.
Benefits
Platform Proof
Platform proof is strong because Alnylam has turned RNAi science into 4 approved therapies, showing the platform works beyond the lab. In 2025, net product revenue reached $2.2 billion, up 29% year over year, which shows real commercial pull. The scorecard should track how often new RNAi programs move from discovery to approvals, not just clinical milestones. That makes platform strength measurable in both science and sales.
Launch Discipline
Launch discipline is visible across 4 products – Onpattro, Givlaari, Oxlumo, and Amvuttra – because management can track new patient starts, coverage, and refill persistence together. Amvuttra's 2025 U.S. ATTR-CM approval added a new growth leg, so launch control matters even more. When starts rise but refill persistence stays strong, adoption is building in a controlled way.
Rare-Disease Visibility
Alnylam's rare-disease focus makes Balanced Scorecard signals clear: a small shift in patient starts, refills, or drop-off can quickly show whether diagnosis, access, and prescribing are improving. With four marketed medicines in 2025, every new patient matters, so even modest gains can move revenue and operating metrics fast.
This also helps tie clinical and commercial outcomes together. In small patient pools, changes in persistence and time-to-start are often more useful than broad volume trends, because they show where the care pathway is breaking.
Portfolio Spread
Alnylam now has four marketed RNAi drugs across rare genetic, cardio-metabolic, hepatic infectious disease, and CNS and eye programs, so its revenue is not tied to one indication.
A Balanced Scorecard can test that spread by tracking revenue mix, pipeline wins, and concentration risk, with ATTR and other genetic franchises balanced against newer programs.
That matters because broader indication coverage can soften shocks if one launch slows or a payer blocks one use case.
R&D Learning Loop
The R&D learning loop lets Alnylam track each RNAi program from discovery to clinic, so management can spot what works across 4 approved medicines and the broader pipeline. That matters because the 2025 scorecard should reward repeatable execution, not one-off trial wins. It also helps convert platform know-how into faster decisions on dose, delivery, and target selection.
- Tracks progress across many RNAi programs
- Builds repeatable, platform-wide execution
Alnylam's 29% Growth Shows RNAi Is Turning Science Into Cash
Alnylam's benefit is clear in 2025: $2.2 billion net product revenue, up 29%, showing the RNAi platform is converting science into cash.
Four approved drugs and the Amvuttra U.S. ATTR-CM launch reduce single-product risk and widen growth paths.
A scorecard can capture this by tracking new starts, persistence, and revenue mix across rare-disease franchises.
| 2025 metric | Value |
|---|---|
| Net product revenue | $2.2B |
| YoY growth | 29% |
| Approved therapies | 4 |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Binary Trial Risk
Binary trial risk is high for Alnylam because one Phase 2 or Phase 3 readout can move the stock more than a full quarter of sales or margin data. In 2025, the company still depended on late-stage inflection points in RNAi, where even a 1 primary-endpoint miss can weaken the whole scorecard. That matters because one clean dashboard cannot offset a failed study in a market that can rerate fast.
Tiny Patient Pools
Alnylam's 2025 rare-disease markets are still very small, so the scorecard can jump on little volume. A few dozen patients can shift prescriptions, persistence, or revenue enough to blur the trend, especially in ultra-rare lines like acute hepatic porphyria, which affects about 1 to 2 people per million. That makes quarterly readouts noisy, because one center or one refill cycle can move the numbers fast.
Payer Friction
Specialty medicines like Alnylam's often hit prior authorization and coverage checks, and the American Medical Association found 93% of physicians said prior authorization delays care. That gap can make the scorecard show strong demand while actual dispense lags. It also distorts customer metrics, since scripts approved later can look like weak conversion.
Metric Lag
Metric lag is a real drawback for Alnylam's Balanced Scorecard. Commercial data often show up 1 to 4 quarters after a clinical win or launch slip, so 2025 revenue and patient-start trends can miss the real shift in demand. That makes the scorecard slower than the market and less useful for fast launch fixes.
Heavy R&D Burden
Alnylam's heavy R&D load is a real scorecard weakness because RNAi drugs need constant discovery work, clinical trials, and new delivery tech to stay ahead. A scorecard focused on near-term sales can miss that this engine only stays competitive if research spend stays high, even when margins look better. For FY2025, that means judging Alnylam on pipeline depth and R&D intensity, not just revenue growth.
Alnylam's 2025 outlook is still driven by trial risk and slow uptake
Alnylam's 2025 scorecard is still exposed to binary trial risk and slow readthrough, so one Phase 2 or Phase 3 miss can outweigh a quarter of commercial progress. Rare-disease demand is also too thin for clean trend lines: acute hepatic porphyria affects about 1 to 2 per million, and prior authorization still delays care for 93% of physicians. That makes the dashboard noisy and lagged.
| Drawback | 2025 data | Impact |
|---|---|---|
| Trial risk | 1 study can move valuation | High rerate risk |
| Access friction | 93% prior-auth delay | Slower scripts |
Get Your Copy
Alnylam Reference Sources
This preview shows the actual Alnylam Balanced Scorecard Analysis document you'll receive after purchase – no sample, no filler. The full report is the same professional file, with the complete content unlocked immediately after checkout. What you see here is exactly what you'll download, ready to use right away.
Frequently Asked Questions
It measures whether Alnylam turns RNAi science into durable commercial value. The cleanest signals are 4 approved medicines, growth in prescriptions, and pipeline progress across 3 broad areas: genetic disease, cardio-metabolic disease, and CNS/eye programs. That mix shows whether the platform is scaling beyond a single rare-disease niche.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.